Positive Expression of MiR-361-5p Indicates Better Prognosis for Breast Cancer Patients

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2016 Aug 9

PMID 27499968

Citations 24

Authors

Zhi-Gang Cao

Yan-Ni Huang

Ling Yao

Yi-Rong Liu

Xin Hu

Yi-Feng Hou

Zhi-Min Shao

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNA-361-5p (miR-361-5p) has been reported to be tumor suppressor in colorectal, gastric and prostate cancer, but as an oncogene in cervical cancer. No previous research has focused on the expression of miR-361-5p and its exact prognostic role in breast cancer (BC).

Methods: In this study, a tissue microarray (TMA)-based miRNA detection in situ hybridization (ISH) with LNA probe was used to detect miR-361-5p expression in 375 BC tissue. The expression level of miR-361-5p in BC and its potential prognostic value was investigated.

Results: Positive miR-361-5p staining was observed in 78.7% (N=295; 78.7% positive, 21.3% negative) in the 375 cases. The clinical outcome of patients with positive miR-361-5p expression [median disease-free survival (DFS) time 95.52 months] was significantly better than that of patients (median DFS time 82.33 months) with negative miR-361-5p expression (P=0.002). Moreover, the prognostic value of miR-361-5p was most significant among patients with triple-negative breast cancer (TNBC) for DFS (P=0.004).

Conclusions: These results indicated that miR-361-5p expression is an independent predictive factor for better prognosis in BC.

Citing Articles

Correlation of Wilms' Tumor 1 (WT1) with Oxidative Stress Markers and Expression of miR-361-5p; New Aspect of WT1 in Breast Cancer.

Pishbin F, Ziamajidi N, Abbasalipourkabir R, Najafi R, Farhadian M Indian J Clin Biochem. 2023; 38(3):338-350.

PMID: 37234179 PMC: 10205927. DOI: 10.1007/s12291-022-01053-9.

The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.

Santana T, de Oliveira Passamai L, de Miranda F, Borin T, Borges G, Luiz W Diagnostics (Basel). 2023; 13(1).

PMID: 36611419 PMC: 9818368. DOI: 10.3390/diagnostics13010127.

ALDH1A3-Linc00284 Axis Mediates the Invasion of Colorectal Cancer by Targeting TGF Signaling via Sponging miR-361-5p.

Ke C, Shen M, Wang P, Chen Z, Lin S, Dong F Int J Genomics. 2022; 2022:6561047.

PMID: 36275636 PMC: 9584677. DOI: 10.1155/2022/6561047.

Stability of circulating microRNAs in serum.

Kupec T, Bleilevens A, Iborra S, Najjari L, Wittenborn J, Maurer J PLoS One. 2022; 17(8):e0268958.

PMID: 36044434 PMC: 9432728. DOI: 10.1371/journal.pone.0268958.

MMP1 regulated by NEAT1/miR-361-5p axis facilitates the proliferation and migration of cutaneous squamous cell carcinoma via the activation of Wnt pathway.

Jiang S, Liu H, Zhang J, Zhang F, Fan J, Liu Y Cancer Biol Ther. 2021; 22(5-6):381-391.

PMID: 34369270 PMC: 8386739. DOI: 10.1080/15384047.2021.1941583.

References

Fan L, Strasser-Weippl K, Li J, St Louis J, Finkelstein D, Yu K . Breast cancer in China. Lancet Oncol. 2014; 15(7):e279-89. DOI: 10.1016/S1470-2045(13)70567-9. View

Wittner B, Sgroi D, Ryan P, Bruinsma T, Glas A, Male A . Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008; 14(10):2988-93. PMC: 3089800. DOI: 10.1158/1078-0432.CCR-07-4723. View

Zhan C, Yan L, Wang L, Jiang W, Zhang Y, Xi J . Identification of reference miRNAs in human tumors by TCGA miRNA-seq data. Biochem Biophys Res Commun. 2014; 453(3):375-8. DOI: 10.1016/j.bbrc.2014.09.086. View

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier A, Cowens J . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31(22):2783-90. DOI: 10.1200/JCO.2012.46.1558. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Di Leva G, Garofalo M, Croce C . MicroRNAs in cancer. Annu Rev Pathol. 2013; 9:287-314. PMC: 4009396. DOI: 10.1146/annurev-pathol-012513-104715. View

Wu X, Xi X, Yan Q, Zhang Z, Cai B, Lu W . MicroRNA-361-5p facilitates cervical cancer progression through mediation of epithelial-to-mesenchymal transition. Med Oncol. 2013; 30(4):751. DOI: 10.1007/s12032-013-0751-0. View

Palmero E, de Campos S, Campos M, de Souza N, Guerreiro I, Carvalho A . Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol. 2011; 34(3):363-70. PMC: 3168173. DOI: 10.1590/S1415-47572011000300001. View

DeSantis C, Fedewa S, Sauer A, Kramer J, Smith R, Jemal A . Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2015; 66(1):31-42. DOI: 10.3322/caac.21320. View

10.

Kanitz A, Imig J, Dziunycz P, Primorac A, Galgano A, Hofbauer G . The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS One. 2012; 7(11):e49568. PMC: 3498195. DOI: 10.1371/journal.pone.0049568. View

11.

Tang Y, Zhou X, Ji J, Chen L, Cao J, Luo J . High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis. Int J Biol Markers. 2015; 30(4):e347-58. DOI: 10.5301/jbm.5000160. View

12.

DAiuto F, Callari M, Dugo M, Merlino G, Musella V, Miodini P . miR-30e* is an independent subtype-specific prognostic marker in breast cancer. Br J Cancer. 2015; 113(2):290-8. PMC: 4506390. DOI: 10.1038/bjc.2015.206. View

13.

Jovanovic M, Hengartner M . miRNAs and apoptosis: RNAs to die for. Oncogene. 2006; 25(46):6176-87. DOI: 10.1038/sj.onc.1209912. View

14.

Sun E, Zhou Q, Liu K, Wei W, Wang C, Liu X . Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci. 2014; 18(19):2783-8. View

15.

Ma F, Song H, Guo B, Zhang Y, Zheng Y, Lin C . MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1. Oncotarget. 2015; 6(19):17404-16. PMC: 4627317. DOI: 10.18632/oncotarget.3744. View

16.

Sempere L . Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?. Expert Rev Mol Diagn. 2014; 14(7):853-69. PMC: 4364265. DOI: 10.1586/14737159.2014.944507. View

17.

Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L . MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). Biochem Biophys Res Commun. 2014; 445(1):151-6. DOI: 10.1016/j.bbrc.2014.01.140. View

18.

Graveel C, Calderone H, Westerhuis J, Winn M, Sempere L . Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press). 2015; 7:59-79. PMC: 4346363. DOI: 10.2147/BCTT.S43799. View

19.

Iorio M, Casalini P, Piovan C, Braccioli L, Tagliabue E . Breast cancer and microRNAs: therapeutic impact. Breast. 2011; 20 Suppl 3:S63-70. DOI: 10.1016/S0960-9776(11)70297-1. View

20.

Ma L, Li G, Wu Z, Meng G . Prognostic significance of let-7b expression in breast cancer and correlation to its target gene of BSG expression. Med Oncol. 2013; 31(1):773. DOI: 10.1007/s12032-013-0773-7. View